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ABSTRACT:
Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and 
the promoter of telomerase reverse transcriptase (TERT) represent two significant 
discoveries in glioma genomics. Understanding the degree to which these two 
mutations co-occur or occur exclusively of one another in glioma subtypes presents 
a unique opportunity to guide glioma classification and prognosis. We analyzed the 
relationship between overall survival (OS) and the presence of IDH1/2 and TERT 
promoter mutations in a panel of 473 adult gliomas. We hypothesized and show that 
genetic signatures capable of distinguishing among several types of gliomas could be 
established providing clinically relevant information that can serve as an adjunct to 
histopathological diagnosis. We found that mutations in the TERT promoter occurred in 
74.2% of glioblastomas (GBM), but occurred in a minority of Grade II-III astrocytomas 
(18.2%). In contrast, IDH1/2 mutations were observed in 78.4% of Grade II-III 
astrocytomas, but were uncommon in primary GBM. In oligodendrogliomas, TERT 
promoter and IDH1/2 mutations co-occurred in 79% of cases. Patients whose Grade 
III-IV gliomas exhibit TERT promoter mutations alone predominately have primary 
GBMs associated with poor median OS (11.5 months). Patients whose Grade III-IV 
gliomas exhibit IDH1/2 mutations alone predominately have astrocytic morphologies 
and exhibit a median OS of 57 months while patients whose tumors exhibit both TERT 
promoter and IDH1/2 mutations predominately exhibit oligodendroglial morphologies 
and exhibit median OS of 125 months. Analyzing gliomas based on their genetic 
signatures allows for the stratification of these patients into distinct cohorts, with 
unique prognosis and survival.
INTRODUCTION
Gliomas are the most common primary malignant 
tumor of the central nervous system and account for 24% 
of brain tumors [1]. Tumor grades range from Grade I to 
Grade IV and are based on histopathological and clinical 
criteria established by the World Health Organization 
(WHO) [1, 2]. Grade I tumors are relatively benign and are 
circumscribed tumors that display a favorable prognosis 
with 94% of patients surviving at 5 years and 91% at 10 
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years [1]. Grade II gliomas are diffusely infiltrative and 
can be divided into astrocytomas and oligodendrogliomas. 
These tumors have the inherent ability to progress to 
higher grade gliomas. In addition to Grade II and III 
astrocytomas and oligodendrogliomas, another subtype 
of glioma presents with a histological appearance of both 
oligodendrogliomas and astrocytomas. These “mixed 
histology” tumors, or oligoastrocytomas also have the 
ability to progress from Grade II to Grade III tumors.  The 
Grade III astrocytomas have the ability to further progress 
into secondary Grade IV glioblastomas (GBM), which 
exhibit a poorer prognosis than the grade III astrocytomas. 
As first described by Scherer in 1940 [3] secondary GBM 
arises as a progression from Grade II and Grade III 
tumors, whereas primary GBM arises de novo and has 
a dismal median OS of 15 months [1]. The progression 
between grades along with the potential for mixed 
histology presents neuropathologists with diagnostic 
challenges that often rely on subjective measures. 
Consequently, diagnoses among different pathologists 
and institutions have weak correlations that may result in 
variable treatment and management of each tumor grade 
[2, 4]. The subjective nature of these analyses stresses the 
importance of an accurate, unbiased, and objective means 
of diagnosis. This is crucial for stratification of patients 
with biologically similar tumors in clinical trials, and 
could aid in the selection of targeted therapeutic regimens. 
The discovery of biomarkers that objectively identify 
each tumor’s unique molecular signature is a necessary 
next-step in managing patient outcomes more effectively. 
Genetic signatures performed on pathologically relevant 
tissues will be a potentially useful supplement to clinicians 
in refining and clarifying patient stratification. 
Characterization of the genetic landscape of 
gliomas has been at the forefront of cancer research in 
order to better aid prognostication and classification of 
clinical outcomes [5, 6]. High-throughput screens have 
paid particular attention to understanding the genomic 
variability between each subgroup of glioma. The Cancer 
Genome Atlas and other groups, including ours, have 
begun to identify the molecular subgroups of these tumors 
and delineate which tumor types harbor which mutations 
[5-12]. For example, IDH1/2 mutations that occur 
frequently in secondary GBMs (>50%) are infrequent in 
primary GBMs (<5%) [8, 12]. 
Recent findings have established frequent 
mutations in the promoter region of telomerase reverse 
transcriptase (TERT) in a multitude of cancers, including 
melanomas, liposarcomas, bladder cancer, urinary tract 
cancers, and gliomas [13-19]. TERT is a subunit of the 
telomerase enzyme that, when expressed, allows cells to 
avoid senescence.  This is especially noted as TERT is 
mutated in high frequencies in cells with low rates of self-
renewal, such as melanocytes, urothelial cells, and glial 
cells [14-16, 20, 21].  Of interest to glioma genomics, 
TERT promoter mutations occur in 70-80% of primary 
GBMs and >70% of oligodendrogliomas, but occur less 
frequently in both lower grade astrocytomas and most 
oligoastrocytomas [16, 17, 22]. 
The discovery of TERT promoter mutations in these 
subsets of gliomas creates an opportunity for genomics 
to supplement histopathological analysis, especially when 
combined with IDH1/2 mutation status. Here, we have 
assessed the characteristic variance between IDH1/2 and 
TERT promoter mutations among several glioma subtypes 
that help refine the diagnosis of gliomas.  The assay, based 
upon three polymerase chain reactions (PCR), provides 
pathologists with a manageable and reliable diagnostic 
supplement in the form of a simple, yet robust genetic 
signature unique to each tumor type. 
RESULTS
TERT promoter mutations are frequent in 
primary GBMs and oligodendrogliomas but 
uncommon in lower grade astrocytoma. 
To assess the prevalence and prognostic impact of 
TERT promoter mutations we sequenced the proximal 
TERT promoter hotspot mutations (C228T and C250T) 
in 473 adult gliomas. We identified TERT promoter 
mutations in 281 (59.4%) tumors (Fig. 1). In agreement 
with previous studies [16, 18, 23], we identified TERT 
promoter mutations in 74.2% of grade IV GBMs 
(178/240). TERT promoter mutations were also common 
in oligodendrogliomas (79.3%); however, TERT promoter 
mutations were less frequently identified in Grade II-III 
astrocytomas (18.2%, 16/88). Furthermore, we observed 
a moderate frequency of TERT promoter mutations in 
oligoastrocytomas (31.0%, 18/58). As expected, GBMs 
were diagnosed in older patients when compared to other 
histologic subtypes studied here (Table 1). Within each 
tumor type, TERT promoter mutations were associated 
with an older age at diagnosis (Table 2).
Co-occurring mutations in TERT promoter and 
IDH1/2.
IDH1/2 mutations are a well-established molecular 
feature of gliomas [12].  To define the co-occurrence of 
IDH1/2 mutations and the presence of TERT promoter 
mutations, we determined the status of IDH1 and IDH2 
mutations in the same cohort of 473 gliomas and identified 
mutations in 47.9% (227/473) of tumors (Fig. 1 and Table 
1). IDH1/2 mutations were much less prevalent among 
GBMs (10%), and much more common in Grade II-
III astrocytomas (78.4%), oligoastrocytomas (86.2%) 
and oligodendrogliomas (96.5%). TERT mutations 
occurred in the absence of IDH1/2 mutations in GBMs 
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(73.3%, 176/240). However, in oligodendrogliomas, 
the TERT promoter mutation always occurred in the 
setting of the IDH1/2 mutation, which is frequent in 
both oligodendrogliomas and astrocytomas (Fig. 1) [12]. 
The cross-tabulation of TERT promoter and IDH1/2 
mutations aligned with three of the four histologic 
subtypes. GBMs were characterized as primarily TERT 
promoter mutant/IDH wildtype (73.3%), Grade II-
III astrocytomas were predominantly TERT promoter 
wildtype/IDH mutant (73.9%), and the majority of 
oligodendrogliomas mainly harbored mutations in both 
the TERT promoter and IDH1/2 (79.3%).  A majority of 
oligoastrocytomas (63.8%) exhibited the IDH mutation 
in the absence of TERT promoter mutations, much like 
Grade II-III astrocytomas; however, a fraction (22.4%) of 
oligoastrocytomas presented with both TERT promoter 
and IDH1/2 mutations, similar to oligodendrogliomas 
(Fig. 1). 
TERT promoter and IDH1/2 mutations have 
distinct tumor distributions and are associated 
with OS.  
We next sought to determine whether the 
combination of TERT promoter and IDH1/2 mutations 
are associated with OS.  Clinical information (survival, 
age at diagnosis, and histopathological diagnosis) was 
available for our cohort of 473 adult gliomas in both 
treated and untreated patients (Table 1).  As grade is a 
well-known prognostic factor in glioma patients, we first 
investigated whether distinct tumor subgroups could be 
distinguished using only TERT promoter and IDH1/2 
mutation status within each grade (Fig. 2, Table 3). 
Among the 112 Grade II gliomas, 103 were characterized 
by either mutations in both TERT and IDH or IDH alone. 
The median OS of those tumors harboring mutations in 
both TERT promoter and IDH1/2, the predominant genetic 
signature in oligodendrogliomas, was longer than those 
tumors with an IDH1/2 mutation only, typically seen in 
Grade II-III astrocytomas (206 months vs. 131 months), 
but this difference was not statistically significant (log-
rank p=0.1754) (Fig. 2A). When stratified by histologic 
diagnosis, oligodendrogliomas had the best median OS 
among Grade II astrocytomas, oligodendrogliomas, and 
oligoastrocytomas, as expected (median OS 205 months). 
Among the 121 Grade III tumors, 60 (50%) had 
IDH1/2 mutations alone and 40 (34%) had mutations 
in both the TERT promoter and IDH1/2. Those with 
mutations in both the TERT promoter and IDH1/2 had 
the largest median OS (127 months), followed by those 
with an IDH1/2 mutation only (median OS 64 months), 
and those with neither mutation (median OS 32 months). 
Tumors with mutations in the TERT promoter alone, which 
was the predominant signature present in primary GBMs 
had the poorest OS (median OS 19 months).  Four distinct 
subgroups of Grade III gliomas were identified when 
stratified by the combination of the TERT promoter and 
IDH1/2 mutation status (log-rank p=0.0008) (Fig. 2B). 
Oligodendrogliomas again had the best median OS when 
Grade III tumors were stratified by histologic subtypes 
(median OS 125 months), but OS did not significantly 
differ among the three histologic subtypes, which were 
astrocytomas, oligodendrogliomas, and oligoastrocytomas 
Fig 1: Distribution of TERT promoter and IDH1/2 mutations in a panel of 473 adult gliomas. Mutational analysis of 473 
adult gliomas for TERT promoter and IDH1/2 mutations. Data are from 240 Grade IV GBM (A), 88 Grade II-III astrocytomas (B), 58 Grade 
II-III oligoastrocytomas (C), and, 87 Grade II-III oligodendrogliomas (D). Mutation status is indicated by color shading, with gray coloring 
indicating wild type sequence, red indicating mutations in the TERT promoter, and green indicating mutations in IDH1/2.
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(log-rank p=0.1626).
A majority of the GBMs were characterized by 
mutations in the TERT promoter alone (73%), and this 
genetic signature also had the worst prognosis (median OS 
11.3 months) (Fig. 2, Table 3). Those without mutation 
in either marker had only a slightly better outcome 
(median OS 17 months), while those with an IDH1/2 
mutation alone, the signature characteristic of Grade II-
III astrocytomas and Grade IV secondary GBMs, had the 
best outcome among the Grade IV tumors (median OS 42 
Table 1: Clinical Characteristics of Cohort
Age (mean, SD) 54.9 13.4 39.0 10.4 42.0 13.2 41.2 11.2
Gender
Male 146 60.8% 54 61.4% 36 62.1% 60 69.0%
Female 94 39.1% 34 38.6% 22 37.9% 37 31.0%
Grade
II 0 0.0% 40 45.4% 28 48.3% 44 50.6%
III 0 0.0% 48 54.6% 30 51.7% 43 49.4%
IV 240 100.0% 0 0.0% 0 0.0% 0 0.0%
Diagnosis Status
Newly Diagnosed 132 55.0% 50 56.8% 30 51.7% 42 48.3%
Recurrent 65 27.1% 35 39.8% 24 41.4% 31 35.6%
Not Available 43 17.9% 3 3.4% 4 6.9% 14 16.1%
TERT  Status
Mutant 178 74.2% 16 18.2% 18 31.0% 69 79.3%
Wildtype 62 25.8% 72 81.9% 40 69.0% 18 20.7%
IDH1/2  Status
Mutant 24 10.0% 69 78.4% 50 86.2% 84 96.5%
Wildtype 216 90.0% 19 21.6% 8 13.8% 3 3.5%
TERT -IDH1/2  Status
TERT  wt / IDH  wt 40 16.7% 7 7.9% 3 5.2% 3 3.5%
TERT  wt / IDH  mut 22 9.2% 65 73.9% 37 63.8% 15 17.2%
TERT  mut / IDH  wt 176 73.3% 12 13.6% 5 8.6% 0 0.0%
TERT  mut / IDH  mut 2 0.8% 4 4.6% 13 22.4% 69 79.3%
1p/19q Status
Wildtype/Wildtype 0 0.0% 21 23.9% 26 44.8% 9 10.4%
Wildtype/19q 0 0.0% 7 7.9% 11 19.0% 0 0.0%
1p/Wildtype 0 0.0% 0 0.0% 2 3.5% 0 0.0%
1p/19q 0 0.0% 2 2.3% 12 20.7% 47 54.0%
Not Available 240 100.0% 58 65.9% 7 12.1% 31 33.6%
GBM (N=240) A (N=88) OA (N=58) O (N=87)
Table 2: Age at diagnosis in gliomas as determined by TERT  promoter genotype
TERT  Mutant TERT  WT p-value
Age (mean ± SD) 57 ± 12 49 ± 16
median yrs 57 52
Age (mean ± SD) 44 ± 10 38 ± 10
median yrs 43 36
Age (mean ± SD) 50 ± 12 38 ± 12
median yrs 50 35
Age (mean ± SD) 42 ± 10 37 ± 14





months). Within the primary and secondary GBMs, using 
the TERT promoter and IDH1/2 alone, we were able to 
distinguish three significantly different subgroups (log-
rank p<0.0001), and these associations remained when 
adjusting for the factors of age and diagnosis (Table 4). 
The TERT promoter mutation is associated with poorer 
OS in GBMs, and as shown in the multivariable model, 
this association was also evident among tumors without an 
IDH1/2 mutation (HR: 1.9, 95% CI: 1.2-2.9).
Given that both Grade III and Grade IV gliomas 
were successfully stratified into distinct subgroups based 
on TERT promoter and IDH1/2 mutational status, and 
that each signature was associated with a similar median 
OS within grade, the effect of histology and genetic 
signature on OS was also examined across the Grade III 
and IV gliomas together (Fig. 3, Table 5A).  When Grade 
III and IV gliomas were examined based on histology, 
GBMs predictably had by far the worst prognosis, 
Fig 2: Overall Survival stratified by TERT promoter and IDH1/2 mutational status and histology within each tumor 
grade. Overall survival was represented by Kaplan Meier plots for individual WHO tumor grade: a) Grade II (n=103), b) Grade III 
(n=121), c) Grade IV (n=218). Only subgroups with at least 10 patients were included in the analyses. Tumors were represented by 
mutations status on the left (TERT promoter status / IDH1/2 status) and histology on the right (A represents Astrocytomas, O represents 
Oligodendrogliomas, and OA represents Oligoastrocytomas).
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and oligodendrogliomas experienced the best survival 
outcome; however, OS among the Grade III astrocytomas 
and oligoastrocytomas was similar and difficult to 
distinguish (Fig. 3A and Table 5A). Nevertheless, when 
genetic signatures were applied to the same cohort of 
tumors, four distinct clinical subgroups emerged (Fig 3B). 
As observed, within Grade III and IV gliomas separately, 
tumors with mutations in both TERT and IDH1/2 had the 
best median OS (oligodendroglioma signature), followed 
by those with an IDH1/2 mutation only (Grade II-III 
astrocytoma and secondary GBM signature). Both tumors 
without mutation in either marker and those tumors with 
a TERT promoter mutation alone had a poorer prognosis, 
with the latter signature having the worst median OS. The 
strength of the association between OS and TERT/IDH1/2 
mutational status is similar to that of OS and histology 
(Generalized R2: 0.3132 and 0.2704, respectively).   
DISCUSSION
Our analysis of this tumor cohort expands upon 
Fig 3: Overall Survival stratified by TERT promoter and IDH1/2 mutational status and histology among Grade III 
and IV patients. Overall survival was represented by Kaplan Meier plots stratified by a) histology (A represents Astrocytomas, O 
represents Oligodendrogliomas, OA represents Oligoastrocytomas, and GBM represents Glioblastoma) and b) TERT promoter / IDH1/2 
mutation status for all Grade III and Grade IV gliomas analyzed in this study.
Table 3: Summary of OS Stratified by TERT promoter and IDH1/2 Mutational Status by Grade
TERT/IDH  status Total # failed
OS in months 
(95% CI)
1 year OS           
(95% CI)
2 year OS       
(95% CI)
5 year OS        
(95% CI)
10 year OS      
(95% CI)
Grade II

































































































** Genotypes with frequencies less than 10 were not included
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previous reports identifying frequent TERT promoter 
mutations in gliomas [16-18, 22, 23], examines the 
association between TERT promoter and IDH1/2 
mutations in glioma, and assesses their joint influence on 
OS. Utilizing a combined analysis of IDH1/2 and TERT 
promoter mutations in adult glioma, we have derived 
a greatly expedited and simplified genetic signature 
of three common glioma subtypes, namely Grade II-
III astrocytomas, oligodendrogliomas, and GBMs. 
Additionally, we show that oligoastrocytomas can be 
further classified. 
Among patients with GBMs, we showed that the 
largest fraction of GBMs present with TERT promoter 
mutations. IDH1/2 mutations are infrequent in these 
tumors and cluster within secondary GBMs. Three distinct 
subgroups were defined by the presence or absence of 
TERT promoter and IDH1/2 mutations. Where patients 
harboring tumors with TERT promoter mutations alone 
had the poorest OS (median 11.3 months), patients with 
tumors bearing no mutations in either TERT or IDH1/2 had 
a slightly better survival (median 16.6 months), and GBMs 
with IDH1/2 mutation alone resulted in the best survival 
(median 42.3 months). Furthermore, these associations 
remained after adjustment for factors such as age. TERT 
promoter mutations predicted poorer OS outcome in 
a multivariate model even in GBMs without IDH1/2 
mutations. This finding is in contrast with previous studies 
that did not report a significant difference in OS between 
TERT promoter-mutated and TERT promoter-wildtype non 
IDH mutated GBMs [23]. This finding will be of particular 
interest to clinicians as it may provide a tool to stratify non 
IDH1/2 mutant GBMs and suggests that combined IDH1/2 
and TERT promoter genotyping will be useful for patient 
management. Because of variable treatment among these 
histological brain tumor groups, further analyses must 
include large cohorts of standardized treatment arms and 




TERT Mutant vs. Wildtype 1 1.901 1.244
IDH1 Mutant vs. Wildtype 1 0.496 0.251
Tumor Status Newly Diagnosed vs. Recurrent 1 0.481 0.340
Age 1 1.019 1.004
*198 tumors with all covariates available are included in the model
Parameter




OS in months 
(95% CI)
1 year OS    
(95% CI)
2 year OS    
(95% CI)
5 year OS     
(95% CI)














































Table 5B: Summary of OS Stratified by TERT  promoter and IDH1/2  Mutational Status in Grades III and IV
TERT /IDH  status Total # failed
OS in months 
(95% CI)
1 year OS     
(95% CI)
2 year OS    
(95% CI)
5 year OS     
(95% CI)
10 year OS    
(95% CI)













































measurements of other genetic features such as MGMT 
status, EGFR wildtype amplification, and the presence 
of EGFRvIII to confirm the validity of our findings. 
At a minimum, our current findings warrant further 
investigation and confirmation by other investigators. 
Also, genetic alterations of the TERT promoter may be 
particularly relevant given the development of therapeutics 
targeted against telomerase. Telomerase inhibitors have 
shown promise for treating GBM in preclinical models 
and are currently under investigation in clinical trials for 
several types of cancer [24-27].
Conversely, IDH1/2 mutations in Grade II-III 
astrocytomas are frequent while TERT promoter mutations 
are uncommon. Grade II-III oligodendrogliomas have 
frequent co-occurring mutations in the TERT promoter 
and IDH1/2. We provide evidence that over 86% 
of oligoastrocytomas in this cohort contain genetic 
signatures representative of either astrocytoma (IDH1/2 
mutations alone) or oligodendroglioma (TERT promoter/
IDH1/2), signatures that we show are associated with 
OS. Reproducibility of oligoastrocytoma diagnosis by 
histology alone displays variable diagnoses between 
neuropathologists within and among different institutions 
[2, 4, 28]. The presence of the TERT promoter and IDH1/2 
mutational status may be particularly useful to refine the 
classification of “mixed” oligoastrocytomas.
In addition to demonstrating the robust nature of 
these mutational patterns, we have further established that 
these genetic signatures are reliable when compared to the 
OS of patients derived from conventional histopathological 
diagnosis. As shown in Figures 2 and 3, mutations in the 
TERT promoter and IDH1/2 effectively stratify patients 
into reproducible subgroups based on survival. This 
phenomenon was independent of grade among high grade 
astrocytomas as Grade III and Grade IV tumors mimicked 
this relationship when analyzed independently (Fig 2). 
Furthermore, the strength of these genetic signatures and 
their association with OS is illustrated by a slightly higher 
R2 (0.3132 vs. 0.2704) than by histology alone.
Two clinical subgroups exist among Grade II 
tumors in the current cohort, as the power of the survival 
analysis was limited due to the smaller number of low 
grade gliomas. The Grade II tumors exhibited genetic 
signatures with mutations in IDH1/2 alone, and tumors 
with mutations in the TERT promoter and IDH1/2. Both 
subgroups had a more favorable prognosis, with a median 
OS of 130.7 months in tumors with IDH1/2 mutations 
alone, and median OS of 205.5 months among patients 
whose tumors harbored TERT promoter and IDH1/2 
mutations. No Grade II tumors exhibited TERT promoter 
mutations alone.
Within Grade III-IV gliomas, those patients with 
the TERT promoter mutations alone had the poorest 
prognosis (median 11.5 months), while tumors bearing the 
events typically representative of astrocytomas (IDH1/2 
mutation) had a more favorable prognosis (median 56.9 
months). Tumors harboring mutations typically seen in 
oligodendroglioma (both TERT promoter and IDH1/2 
mutation) had a more favorable prognosis (median 
125.2 months). Tumors that did not harbor mutations in 
either the TERT promoter or IDH1/2 comprised a unique 
clinical group with a short OS (median OS 17.2 months) 
that was distinct from TERT promoter mutated gliomas 
(median OS 11.5 months) (Table 5B). As these gliomas, 
wildtype for both TERT promoter and IDH1/2 mutations, 
represented a clinically distinct unit (Fig. 2B and 2C) 
further investigation is required to delineate critical driver 
mutations in this subset of gliomas.
It is of interest to note that within each tumor type, 
a minority of tumors bore the genetic signature typically 
associated with other histological subtypes. In particular, 
13.6% (12/88) of Grade II-III astrocytomas bore TERT 
promoter mutations alone and occasional Grade II-III 
astrocytomas harbored both TERT promoter and IDH1/2 
mutations (4/88, 4.6%). This suggests that at least 
genetically, these tumors may be more similar to GBM 
and oligodendroglioma, respectively. Oligodendrogliomas 
were almost exclusively TERT promoter and IDH1/2 
mutated (79.3%, 69/87), but a fraction, 17.2% (15/87) 
harbored mutations in IDH1/2 alone. In our cohort, 
no oligodendroglioma cases harbored TERT promoter 
mutations alone. A minor fraction of GBMs (0.8%, 2/240) 
contained mutations in both the TERT promoter and 
IDH1/2 suggesting they were treated oligodendrogliomas 
that were diagnosed as small cell GBMs. 
Loss of chromosomal arms 1p and 19q is a well-
known genetic event associated with oligodendrogliomas 
that many neuropathologists use as a reliable test for 
diagnosing oligodendroglioma, a tumor generally 
associated with favorable prognosis and response to 
chemotherapy [29-32]. As a secondary analysis, the 69 
oligodendrogliomas with 1p/19q status available were 
analyzed for an association with TERT promoter/IDH1/2 
mutational status. All 44 oligodendrogliomas with TERT 
promoter and IDH1/2 mutations also had the 1p/19q allelic 
deletions and all but 3 of the 47 tumors with 1p/19q allelic 
losses also contained both TERT promoter and IDH1/2 
mutations, indicating that IDH1/2 and TERT promoter 
mutational analysis may be comparable prognostic 
markers to 1p and 19q in oligodendrogliomas (Fisher 
exact p<0.0001).
This study supports genotyping of TERT promoter 
and IDH1/2 in gliomas as a rapid economical test requiring 
little tumoral DNA that could help inform clinicians as 
to the predicted OS of these tumors that may differ from 
their predicted outcomes based on conventional histology 
alone. The TERT promoter mutations analyzed in this 
study lay only 22 base pairs apart, allowing for PCR 
amplification in a single amplicon. Additionally, the most 
frequent mutations in IDH1 and IDH2 occur in hotspot 
residues located at resides R132 and R172, respectively. 
Combined together, these three PCR amplicons allow for 
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expedient turnaround, objective interpretation, and vast 
economic advantages to glioma patients. 
The TERT promoter/IDH1/2 mutational profiles 
of each tumor type can be used in several aspects of 
the clinical process including stratification of patients, 
examination of therapeutic response, and selection of 
treatment, among others. Given the background genes 
previously discovered in glioma, we hypothesize TERT 
promoter and IDH1/2 mutations as the major driver 
genes that are consistently found in low-grade and high-
grade adult gliomas. These gene mutation assays will 
support and expedite the diagnosis of brain tumors while 
supplementing histopathological evaluation. Measurement 
of these biomarkers could further increase the fidelity of 
glioma diagnosis in a rapid and cost-effective manner. 
Furthermore, the simplicity and affordability of these 
tests underscore their importance as a tool to aid 
neuropathologists in glioma diagnosis. Notably, these 
signatures can be applied to cases that present atypical 
morphologic features in standard histopathological 
analysis. Taken together these findings simplify the 
genetic classification of glioma. The ability of these 
genetic signatures to stratify patients will refine and clarify 
the diagnostic accuracy of pathologists by supplementing 
standard histopathological criteria with genetic mutational 
analysis. 
METHODS
Sample Collection, Processing, and Sequencing
Adult glioma (18 ≥ years old) and corresponding 
clinical information were obtained with consent and 
Institutional Review Board approval from the Preston 
Robert Tisch Brain Tumor Center BioRepository at 
Duke University in accordance with the Health Insurance 
Portability and Accountability Act. Newly diagnosed 
versus recurrent glioma status and vital status were 
determined by clinical chart review. Fresh frozen 
tissue sections (first and last sections from the block, 
stained with hematoxyline and eosin) were reviewed 
by a board-certified neuropathologist (REM) to confirm 
original clinical histopathologic diagnosis and to ensure 
intervening studied sections contain ≥ 80% tumor cells. 
DNA was extracted from 240 Grade IV GBMs, 88 Grade 
II and Grade III astrocytomas, 58 Grade II and Grade 
III oligoastrocytomas, and 87 Grade II and Grade III 
oligodendrogliomas. Of the 473 tumors, 160 gliomas 
had been analyzed in our previous studies of the TERT 
promoter [16]. Isolated DNAs were PCR amplified for the 
TERT promoter, exon 4 of IDH1, and analyzed via Sanger 
sequencing for 473 tumors as described previously [12, 
16, 33]. Additionally, on those cases that did not harbor 
mutations in IDH1 we amplified exon 4 of IDH2 and 
analyzed them via Sanger sequencing.  1p and 19q copy 
number was evaluated by microsatellite marker analysis 
and via 1p and 19q FISH testing in a certified clinical 
laboratory as described previously [12, 29, 34].
Statistical Methods
Clinical and demographic characteristics at the 
time of diagnosis were summarized for all patients and 
stratified by histologic tumor type. Means and standard 
deviations were used to describe interval variables, 
whereas frequency distributions were used to describe 
categorical variables. Unpaired t-tests were used to 
compare the mean age of patients with and without 
TERT promoter mutations. The Kaplan-Meier estimator 
was used to describe OS. OS was defined from time of 
surgery to death or last follow-up. Multivariable Cox 
models were used to assess the effect of TERT promoter 
and IDH1/2 mutations on OS adjusting for baseline tumor 
characteristics.  The generalized R2 statistic was used to 
assess the strength of association between covariates. 
Associations between categorical variables were analyzed 
using Fisher exact tests.
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